Scientists hunt for clues in bladder Cancer's surrounding tissue
NCT ID NCT07525349
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines stored tumor samples from 100 bladder cancer patients who had their bladder removed. Researchers will measure the amount of supportive tissue, immune cells, and immune clusters near the tumor. The goal is to see if these features are linked to how long patients survive, which could lead to better risk prediction in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict survival and tailor treatment for bladder cancer patients.
- What could go wrong
- This is a small, retrospective, single-center study that only looks at past samples. It cannot prove that any treatment works, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of patients who underwent radical cystectomy for muscle invasive urothelial carcinoma at the South Egypt Cancer Institute (SECI) between 2018 and 2024.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who underwent radical cystectomy for muscle invasive urothelial carcinoma. * Treated at the South Egypt Cancer Institute (SECI) between 2018 and 2024. Exclusion Criteria: * Cases with non-urothelial histological subtypes (e.g., pure squamous cell carcinoma). * Patients who received neoadjuvant chemotherapy or radiotherapy. * Cases with missing or inaccessible clinical follow-up data. * History of prior or concurrent malignancy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bladder cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lab-Grown tumor organoids could pick the right bladder chemo
- A pill instead of surgery? trial tests vepugratinib against Low-Grade bladder cancer
- Can tumor genes decide who keeps their bladder?
- Lab-Grown tumor models could match patients to the right cancer drug
- Can heated saline during bladder surgery stop tumors from coming back?
- Can a new drug shrink tumors that resist standard care?